Fredag 14 Mars | 05:21:55 Europe / Stockholm

Svenska | English

Oculis Holding

Filter

År

Typ

Språk

Rensa

2025-03-11 21:30:00 Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins 2440,00 ISK | -2,40%

2025-03-11 21:30:00 Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update 2440,00 ISK | -2,40%

2025-03-05 10:00:00 Oculis to Present at Upcoming March Investor Conference 2620,00 ISK | +3,15%

2025-03-03 09:18:33 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2740,00 ISK | -0,72%

2025-02-14 01:40:48 Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum 3020,00 ISK | -1,31%

2025-02-14 01:40:48 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares 3020,00 ISK | -1,31%

2025-02-14 01:39:36 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares 3020,00 ISK | -1,31%

2025-02-08 00:35:06 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 3180,00 ISK | +0,63%

2025-01-31 22:00:00 Oculis updates share capital for its existing at-the-market offering program 3260,00 ISK | +3,82%

2025-01-21 22:00:00 Oculis Publishes Notification of Major Changes in Voting Rights 3200,00 ISK | -1,23%

2025-01-20 23:00:00 Oculis Publishes Notification of Major Changes in Voting Rights 3240,00 ISK | +3,18%

2025-01-06 09:53:25 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-04 00:48:20 Oculis Publishes Notification of Major Changes in Voting Rights 2470,00 ISK | +2,07%

2024-12-06 22:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2140,00 ISK | 0,00%

2024-11-29 10:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 2220,00 ISK | -0,89%

2024-11-27 10:15:47 Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities 2220,00 ISK | +4,72%

2024-11-13 10:00:00 Oculis to Present at the Stifel 2024 Healthcare Conference 2100,00 ISK | -2,78%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

2024-11-07 10:00:00 Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins 2330,00 ISK | -4,51%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

2024-10-21 19:04:57 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees 2120,00 ISK | +9,84%

2024-10-21 10:00:00 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees 2120,00 ISK | +9,84%

2024-10-15 10:00:00 Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 1960,00 ISK | -1,01%

2024-10-02 10:00:00 Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer 1670,00 ISK | +1,83%

2024-09-19 19:00:00 Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award 1630,00 ISK | -0,61%

2024-08-29 10:00:00 Oculis to Present at Upcoming September Investor Conferences 1680,00 ISK | 0,00%

2024-08-27 22:00:00 Oculis Publishes Consolidated Q2 Financial Statements and MD&A 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis Reports Q2 Financial Results and Provides Recent Company Update 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update 1650,00 ISK | +1,85%

2024-08-15 14:00:00 Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer 1640,00 ISK | 0,00%

2024-07-30 22:10:00 Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference 1600,00 ISK | 0,00%

2024-06-27 12:30:57 Oculis and EURETINA Announces the Ramin Tadayoni Award 1665,00 ISK | +0,30%

2024-06-10 11:00:00 Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð 1640,00 ISK | -1,20%

2024-06-10 11:00:00 Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy 1640,00 ISK | -1,20%

2024-06-04 19:47:10 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1620,00 ISK | -0,31%

2024-05-30 10:00:00 Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board 1630,00 ISK | 0,00%

2024-05-30 10:00:00 Oculis birtir niðurstöður aðalfundar 2024 og tilkynnir um skipanir í stjórn og vísindaráð 1630,00 ISK | 0,00%

2024-05-30 10:00:00 Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board 1630,00 ISK | 0,00%

2024-05-17 22:30:00 Oculis updates share capital for its existing at-the-market offering program 1670,00 ISK | -0,60%

2024-05-08 22:10:00 Oculis Reports Q1 2024 Financial Results and Provides Company Updates 1750,00 ISK | -0,57%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden